Valproic acid adjunctive therapy for HIV-associated cognitive impairment: a first report.
In vitro and animal model data demonstrate that valproic acid (VPA) can ameliorate HIV-associated neurotoxicity. The authors conducted a pilot 10-week placebo-controlled study of VPA 250 mg twice daily in 22 HIV-infected individuals with (n = 16) and without (n = 6) cognitive impairment. VPA was safe and well tolerated, with trends toward improved neuropsychological performance and brain metabolism in the impaired subjects.
Schifitto
G
G
Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA. giovanni.schifitto@ctcc.rochester.edu
Peterson
D R
DR
Zhong
J
J
Ni
H
H
Cruttenden
K
K
Gaugh
M
M
Gendelman
H E
HE
Boska
M
M
Gelbard
H
H
D015526:AIDS Dementia Complex / Q000188:drug therapy* / Q000378:metabolism / Q000523:psychology; D000328:Adult; D044966:Anti-Retroviral Agents / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000378:metabolism / Q000523:psychology; D015497:HIV-1; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D014635:Valproic Acid / Q000627:therapeutic use*
D044966:Anti-Retroviral Agents; D014635:Valproic Acid